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Abstract
Background: Concerns for morbidity after a pancreaticoduodenectomy (PD) has led to practitioners
adopting endoscopic resection or ampullectomy in the treatment of T1 ampullary cancer (AC). It was
hypothesized that survival for patients undergoing local resection of AC was inferior to those undergoing
a PD.
Methods: All the data of patients with AC reported in the Surveillance, Epidemiology and End Results
(SEER) database between 2004 and 2010 were collected. Five-year survival rates according to nodal
disease and histological type were compared.
Results: There were 1916 cases of AC; 421 (22%) had T1 disease. Among those with T1 disease, 217
(51%) received endoscopic surveillance, 21 (5%) underwent local resection/ampullectomy, 20 (5%)
underwent ampullectomy with regional lymphadenectomy and 163 (39%) underwent PD. For patients
with complete nodal staging (PD, n = 163), 35 (22%) had metastatic disease in the nodes. Grade was
significantly associated with node positivity (P = 0.007). In multivariate models, survival was improved with
either an ampullectomy with regional lymphadenectomy [hazard ratio (HR) 0.19; 95% confidence interval
(CI) 0.05–0.61, P < 0.005] or a PD (HR 0.23; 95% CI 0.15–0.36, P < 0.001).
Conclusion: Patients with T1 AC have a high risk for nodal metastases especially if they are higher-
grade lesions. Nodal clearance with a lymphadenectomy or a PD is essential for long-term survival in
these patients.
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Introduction
Adenocarcinoma of the ampulla of Vater (AC) is a relatively
uncommon malignancy with an incidence of less than 1% of all
gastrointestinal malignancies. It is the second most common
cancer arising in the periampullary region comprising 6–20% of
periampullary tumours.1–3 Unlike pancreatic adenocarcinoma, AC
has a more favourable prognosis with 5-year survival rates ranging
from 30–60% after surgery.4–6 The improved outcomes of AC
compared with pancreatic adenocarcinoma have been largely
attributed to the higher rate of tumour resectability, more favour-
able histology, as well as less likelihood for lymphatic and
perineural invasion.7 Currently, resection remains the only cura-
tive therapy option for AC.
Cancers of the ampulla are usually reported as single institu-
tional experiences with relatively small sample sizes, and only a
few have examined survival beyond 5 years.3–8 This approach
often makes it difficult to exclude institutional variability in
diagnostic criteria, clinical outcome and selection bias. The
development of national health registries has provided a more
rapid means of access to the accumulation of population-based
histopathological and clinical data. Such data have been cata-
logued according to site, morphological and clinical nomencla-
tures. Initiated in 1973, the Surveillance, Epidemiology and End
Results Registry (SEER) of the National Cancer Institute is one
such registry, now robust enough, where clinical and descriptive
characteristics of uncommon tumours can be assessed at a
population level.9,10
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AC is widely treated by a pancreaticoduodenectomy (PD)
because of its propensity to spread to lymph nodes and a high
incidence of recurrence.11 Fit patients with tumours exhibiting
high-grade dysplasia or adenocarcinoma are generally treated by
PD with low recurrence rates.12 Recent series report 5-year post-
operative survival rates of 53–68%.13 The peri-operative mortality
rate for PD has declined and is widely accepted at high volume
centres where the procedure is routinely performed, but morbid-
ity after PD remains high.14 Local resection is a less invasive and
potentially equally effective alternative for cancers with favourable
prognostic features.15 Local resection of ampullary tumours has
been performed for a century but remains controversial. The use
of this procedure for benign conditions is clear, but its place, if
any, in the management of AC remains ill defined. Successful
endoscopic removal of T1 cancers has also been reported but is
not widely practiced.16–18 Selection criteria have been suggested
and small series in high-risk individuals have been reported. The
aim of this study was to investigate the outcomes of endoscopic
and local resection of AC by comparison with PD. We hypoth-
esized that survival for patients undergoing endoscopic or local
resection of AC was inferior to those undergoing a PD.
Patients and methods
A retrospective cohort study was performed utilizing the SEER
database. Patients with pathologically confirmed AC from 2004 to
2010 were identified by ICD-3 histology codes 8140/3, adenocar-
cinoma not otherwise specified (NOS), combined with site code
C24.1, ampulla of Vater. Inclusion criteria required that patients
have T1 disease by American Joint Committee on Cancer (AJCC)
staging (tumour limited to the ampulla of Vater or sphincter of
oddi) and no evidence of metastatic disease. Inclusion was
restricted to 2004 onwards, owing to the improvements in the
staging variables and the inclusion of the CS Extension variables.
Patients with incomplete AJCC staging and neoplasms other than
adenocarcinoma were excluded from the analysis. Data were
abstracted using the SEER*Stat software, version 8.0.4, National
Cancer Institute, Washington, DC, USA.
Clinicopathological characteristics obtained included TNM
stage, histological type, patient demographics, adjuvant radiation
and type of resection. The patient cohort was stratified by extent
of resection. Extent of surgery was classified into four groups: (i)
endoscopic surveillance/ no surgery, (ii) local resection/
ampullectomy without a lymphadenectomy, (iii) ampullectomy
with a lymphadenectomy, and (4) radical resection (PD). Endo-
scopic surveillance/no resection was defined according to the
SEER 2013 surgery coding manual as no surgery of the primary
site (code 00 or code 10–14 which include destruction of tumor
with ablation/photodynamic therapy/cryotherapy with no
pathology specimen). A local resection was defined as partial to
total surgical removal of the primary tumour (codes 20–30). A
radical resection (PD) was defined as total removal of the primary
site with resection of adjacent organs (code 40 to 60). Local resec-
tion was also subclassified according to performance of a
lymphadenectomy. The SEER database codes lymph nodes based
on assessment at final pathology. They are coded by the number of
lymph nodes and not location of the lymph node.
Statistical analysis
Statistical analyses were performed with Stata/MP 10.0 for
Windows (StataCorp, College Station, TX, USA). Alpha was set at
0.05. The Kruskal–Wallis test was used for non-parametric analy-
sis of continuous variables, whereas categorical variables were
analysed with the chi-squared test. Survival was assessed with the
Kaplan–Meier method, and Cox proportional hazards models
were used to assess independent predictors of survival. The overall
survival time (OS) was calculated from the time of surgery to the
time of death as defined by the SEER registry.
Results
Patient characteristics
From 2004–2010, there were 1916 cases of ampullary cancer; 421
(22%) had T1 disease. The median age at diagnosis was 77 years
[interquartile range (IQR): 67.5–83]. The majority of patients
were male (n = 225, 52%) and white (n = 356, 82%). The demo-
graphic, clinical and tumour-specific pathological characteristics
between treatment groups are presented in Table 1.
Tumour characteristics
The median tumour size for the entire cohort was 1.5 cm (1.0–
2.2), which was significantly larger in the surveillance only arm (P
< 0.001, Table 1). The median number of nodes examined in
patients undergoing a radical resection (PD) was 10 (4–16). For
patients with complete nodal staging (PD, n = 163), 35 (22%) had
metastatic disease in the nodes. Histological grade was missing in
21% (n = 91) of the collective cohort. Grade was significantly
associated with node positivity with 10% positivity in well-
differentiated (n = 61), 12% in moderately-differentiated (n =
163), and 27% in poorly-differentiated tumours (n = 85; P =
0.007). Tumour size ≥1 cm was not associated with node positivity
(P = 0.95).
Therapy characteristics
Of the 421 patients, 217 (51%) received surveillance/endoscopic
treatment only, 21 (5%) underwent local resection/ampullectomy
alone, 20 (5%) underwent ampullectomy with regional
lymphadenectomy and 163 (39%) underwent a PD. The majority
of the patients in the surveillance arm were not recommended for
surgery (n = 155, 71%), whereas 29 (13%) patients refused
surgery. No patients received fulguration/cryotherapy/
photodynamic therapy. Radiation was administered more fre-
quently in patients with node positive disease (27% versus 11%, P
= 0.001) and in those undergoing a lymphadenectomy (Table 1).
Effect of prognostic factors on survival
Patients undergoing radical surgery had a significantly improved
overall survival (mean survival 5 versus 2 years for those with
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surveillance alone, P < 0.001, Table 1). The median survival was
not reached for those undergoing a lymphadenectomy, and hence
we modelled mean survival assuming either censorship at last
month of follow-up or exponentially assuming the rate of death to
be constant (Table 1). Unadjusted Kaplan–Meier curves showed
improved survival with all resection arms compared with
surveillance/ no resection (Fig. 1). However, after adjusting for
demographic characteristics, node positivity was significantly
associated with a worse survival [hazard ratio (HR) 2.2; 95%
confidence interval(CI) 1.3–3.8, P = 0.003] in multivariate
models. We chose not to include node positivity in our models
trying to assess the effect of surgical resection, as node status was
not assessed for surveillance/ endoscopic resection or local resec-
tion only arms. Survival was improved with either an
ampullectomy with regional lymphadenectomy (HR 0.19; 95% CI
0.05–0.61, P < 0.005) or a PD (HR 0.23; 95% CI 0.15–0.36, P <
0.001) in multivariate models adjusted for age, gender, race, radia-
tion therapy and tumour size (Table 2). Although local resection
without lymphadenectomy did show improved survival, the
change in hazard ratio as compared with surveillance/no resection
was not as great as the regional lymphadenectomy or PD groups
(HR 0.33; 95% CI 0.13–0.82, P < 0.02).
Discussion
In recent years, the increasing experience with endoscopy and
otherwise low morbidity rates associated with this technique for
the management of ampullary masses has resulted in some studies
suggesting that T1 ACs may be approached by less invasive
means.17–19 Some surgeons have also proposed performing limited
resections for early stage AC in order to circumvent the potential
morbidity associated with a radical resection.20,21 However, the
relative scarcity of the disease has created difficulties when
attempting to assess outcomes after the surgical management of
AC. Most studies suffer from small sample sizes or provide aggre-
gate data on ‘peri-ampullary’ neoplasms.17,22–24 Evidence of
Table 1 Demographics and clinical and tumour-specific pathological characteristics between treatment groups
Variable Endoscopic
Surveillance/
No Surgery
(n = 217)
Local Resection (No
Lymphadenectomy)
(n = 21)
Local Resection with
lymphadenectomy
(n = 20)
Radical
Resection
(n = 163)
P-value
Age (years) 81 (75–85) 84 (72–89) 64 (57–73) 72 (62–77) 0.0001a
Male gender 114 (52%) 9 (43%) 11 (55%) 85 (52%) 0.85
Grade (n = 321)
Well differentiated 24 (18%) 5 (29%) 6 (33%) 32 (21%) 0.79
Moderately differentiated 68 (51%) 8 (47%) 9 (50%) 80 (53%)
Poorly differentiated 41 (31%) 4 (24%) 3 (17%) 40 (26%)
Undifferentiated 1 (0.7%) 0 (0%) 0 (0%) 0 (0%)
Race
White 185 (85%) 14 (67%) 17 (85%) 130 (80%) 0.01a
Black 16 (7%) 1 (5%) 2 (10%) 6 (4%)
Other 16 (7%) 6 (28%) 1 (5%) 27 (16%)
Radiation
No radiation 216 (99%) 19 (90%) 14 (70%) 141 (86%) <0.001a
Adjuvant radiation 1 (0.4%) 2 (9%) 5 (25%) 22 (13%)
Neoadjuvant radiation – 0 (0%) 1 (5%) 0 (0%)
Median number of lymph
nodes examined
– – 12 (5–17) 10 (4–16) 0.38
1 lymph node positive – – 0 16 (10%)
≥2 lymph nodes positive – – 4 (20%) 19 (12%)
Tumour size (cm) 2 (1.5–3) 2 (1.1–3) 1.5 (1–2) 1.3 (9-2) 0.001a
Median survival (months) 16 (12–22) 58 (16-) Not reached Not reached
Mean survival (restricted to
longest follow-up time
in months) [mean(SE)]
24 (2.5) 55 (9.2) 53 (6.4) 64 (2.7)
Mean survival in months
(exponentially declined
to zero, mean)
31 (= 2.5 years) 87 (= 7.2 years) 199 (= 16.5 years) 229 (= 18 years)
aStatistically significant at alpha = 0.05.
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oncological equivalence for endoscopic or local resection when
compared with a radical resection is also lacking. Therefore we
sought to utilize the SEER Registry to capture a larger cohort of
patients in attempt to better understand the disease, and critically
assess the management of patients with early stage AC. In the
present study, patients with T1 disease demonstrated a high level
of lymph node metastases thereby highlighting the importance of
a lymphadenectomy in this patient cohort. More importantly,
data from this study provides important information on the sur-
vival of patients after resection of AC. Specifically, the present
study reveals that endoscopic surveillance and ampullectomy
without a lymphadenectomy can result in suboptimal outcomes.
Currently there is insufficient data to determine if an extended
resection aids only in staging or if it contributes to increased cure
rates. Among patients with AC, one of the most important
clinicopathological variables to influence survival is the presence
of lymph node metastasis.22,25 In fact, the presence of lymph node
metastasis was associated with a median survival of 36 months
compared with a median survival not reached at current follow-
up. An adequate lymph node dissection at the time of surgery for
AC not only provides important prognostic information, but also
may decrease the risk of local recurrence.26 Park et al. showed that
lymph node metastasis was the most important risk factor for
recurrence after a curative resection.27 Branum et al. reported that
six out of eight patients developed a recurrence after a local
ampullectomy.28 Lindell et al. showed that local recurrence was
diagnosed in 22% of patients after PD as compared with 80% of
patients after local resection (P = 0.001).29 Feng et al. reported
tumour recurrence in 23.3% of patients after a PD and 48.0% of
patients after local resection (P = 0.035).30 Although in the present
study recurrence data were unable to be captured, the significant
improvement in overall survival for the cohort of patients that
underwent a lymphadenectomy suggests that adequate tumour
extirpation is also contingent upon clearing of the local lymph
nodes.
Certainly staging is also important in directing patients towards
appropriate adjuvant therapies. Some authors have suggested that
an ampullectomy without a lymphadenectomy is an adequate
therapy for patients with T1 AC owing to the low incidence of
lymph node metastasis.31–33 However, data from this study found
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Figure 1 Overall survival by surgery type for T1 ampullary adenocarcinoma
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this decidedly not to be the case. Although the risk of lymph node
metastasis increased with worse histology, the incidence of lymph
node metastasis was still clinically significant in patients with T1
disease (10%–27.0%). Our findings are consistent with data from
smaller series that have noted an incidence of lymph node metas-
tasis of 20% to 25% for patients with T1–T2 disease.22 Lindell et al.
analysed 92 patients with cancer of the ampulla of Vater and
demonstrated a 5-year survival of 10% for patients undergoing
only local resection. The authors concluded that local resection
played a limited role in carefully selected patients.29 These data
strongly suggest that even patients with early AC have a high risk
of lymph node metastasis and are best served with an operation
that includes lymph node dissection and clearance. Although our
study showed similar survival with PD or local ampullectomy
with a lymphadenectomy, our institutional bias is to favour PD
rather than local ampullectomy with a lymphadenectomy in
appropriate surgical candidates because the mortality associated
with a PD is low when performed at high-volume centres.34
The present study has several limitations inherent to any
population-based registry. Although the SEER database allows for
longitudinal examination of population-based cancer data, it
lacks comprehensive outpatient data such as the use of adjuvant
chemotherapy, presence of pre-existing comorbidities and
tumour margin status. Other parameters including perineural and
lymphovascular invasion that have been identified by others as
important predictors of outcome are not included for evaluation
in SEER. In addition, the surgical operative and endoscopic pro-
cedure notes are not available for review. Therefore, the location of
lymph nodes examined in the ampullectomy with the
lymphadenectomy group is unknown. The ampullectomy groups
also have small sample sizes which may have influenced their
overall survival. Additionally, whether or not endoscopic resec-
tions were truly for curative intent versus diagnostic alone may
explain the worse survivals in the endoscopic surveillance group.
It may also be as a result of selection bias as the 71% that were not
offered surgical resection may not have been appropriate surgical
candidates owing to the presence of comorbidities and older age.
Lastly, this study is limited by the inability to capture recurrence
data. However, the strengths of SEER remains in its ability to
broadly cross-section the true population, capture a large cohort
of patients with rare diseases and assess current trends in the
medical community.
In conclusion, the present study is a national, population-based
analysis of outcomes for AC. Our research confirms a high level of
lymph node metastases and highlights the importance of a
lymphadenectomy in those patients with T1 ACs. More impor-
tantly, our data shows that endoscopic surveillance and
ampullectomy without a lymphadenectomy can result in subop-
timal outcomes. Although our study showed a similar survival
with PD or local ampullectomy with a lymphadenectomy, our
institutional bias is to favour PD rather than local ampullectomy
with a lymphadenectomy in appropriate surgical candidates
because the mortality associated with a PD is low when performed
at high-volume centres.
Table 2 Uni- and multivariate analysis of overall survival for patients with ampullary adenocarcinoma
Variable Univariate Hazards (95% CI) P-value Multivariate Hazards (95% CI) P-value
Age at diagnosis 1.03 (1.01–1.05) <0.001a 1.01 (0.99–1.02) 0.19
Female gender 1.12 (0.80–1.57) 0.49 1.05 (0.74–1.49) 0.78
White – 1
Black 0.96 (0.48–1.89) 0.91 1.0 (0.50–1.99) 1.0
Other 0.64 (0.36–1.13) 0.13 0.69 (0.38–1.22) 0.20
Grade (n = 321) Excluded due to missing data
Well differentiated 1 –
Moderately differentiated 0.98 (0.59–1.63) 0.96 –
Poorly Differentiated 1.24 (0.72–2.17) 0.43 –
Tumour size (n = 243) Excluded due to missing data
Tumour size <1 cm 1 –
Tumour size ≥1 cm 1.52 (0.77–2.99) 0.23 –
Resection type
Surveillance only 1 1 1
Local resection (no lymph nodes) 0.31 ((0.12–0.76) 0.01a 0.33 (0.13–0.82) 0.02a
Local resection with lymphadenectomy 0.18 (0.05–0.56) 0.003a 0.19 (0.05–0.61) 0.005a
Radical resection 0.19 (0.13–0.30) <0.001a 0.23 (0.15–0.36) <0.001a
No radiation – 1
Radiation 1.37 (0.89–2.09) 0.14 1.2 (0.76–1.80) 0.462
aStatistically significant at alpha = 0.05.
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